Explained: How the BINSA Bill Could Tighten US Scrutiny of Chinese Biotech Investments

Amid growing strategic competition between the United States and China, senior American lawmakers have introduced legislation aimed at tightening oversight of US investments in China's biotechnology sector.

Chairman of the House Select Committee on China, John Moolenaar, and Congresswoman Debbie Dingell have unveiled the Biotech Investment National Security Act (BINSA), a proposal designed to bring certain biotechnology-related investments under stricter national security review.

The move reflects broader concerns in Washington that American funding, technology and expertise may be helping accelerate China's rise in industries viewed as critical to future economic and military power.

What would the proposed legislation do?

If passed, the Biotech Investment National Security Act would require investments in key biotechnology fields to undergo review under the framework established by the Comprehensive Outbound Investment National Security (COINS) Act.

The legislation would cover areas such as pharmaceutical development, biologics manufacturing, and clinical research and development. Lawmakers argue that these sectors are increasingly important not only for healthcare but also for national security and supply-chain resilience.

By expanding oversight of outbound investments, the bill seeks to ensure that American capital is not inadvertently contributing to the growth of strategic industries in China.

Why are US lawmakers concerned about China's biotech sector?

Supporters of the legislation contend that biotechnology is becoming one of the most important industries of the future, with applications ranging from medicine and agriculture to advanced manufacturing and national defence.

According to lawmakers backing the bill, China's growing capabilities in biotechnology could eventually give Beijing greater influence over global pharmaceutical supply chains and critical medical technologies.

There is particular concern that US companies partnering with Chinese firms could help transfer expertise, resources and market advantages that strengthen China's position in the sector.

What has John Moolenaar said about the risks?

John Moolenaar argued that some American pharmaceutical companies are entering into partnerships that could ultimately weaken US competitiveness.

"American companies are making dangerous deals with Chinese biotech firms that jeopardise the future of American pharmaceutical manufacturing," Moolenaar said.

He further warned that unchecked investment could allow China to gain leverage over critical supply chains while weakening America's research ecosystem and industrial base.

Why does Debbie Dingell view biotechnology as a strategic industry?

Congresswoman Debbie Dingell stressed that biotechnology will play a major role in shaping the future of multiple sectors, including medicine, agriculture, manufacturing and national security.

She argued that the United States must reduce potential dependence on China for pharmaceutical ingredients, drug development and medical supply chains.

"The United States cannot afford to become dependent on the People's Republic of China for critical pharmaceutical ingredients, drug development, or medical supply chains."

According to Dingell, strengthening domestic biotechnology and pharmaceutical industries is essential for protecting patients, supporting job creation and safeguarding long-term national health and security interests.

What could be the broader implications of the bill?

The proposed legislation is the latest sign of intensifying US efforts to scrutinise economic ties with China in sectors considered strategically sensitive. If enacted, it could affect how American companies structure partnerships, investments and research collaborations involving Chinese biotechnology firms.

The measure also highlights the growing role of national security considerations in shaping US economic and industrial policy, particularly in industries that are expected to drive innovation and global competitiveness in the coming decades.

(With inputs from ANI)